




1^E EDITION DU SÉMINAIRE SAODA Sommeil France / Benin à Cotonou



**Du 25 au 29 Mai 2022
Palais des congrès de Cotonou**

Sujet : SAOS SNA ET SCM

Orateurs : DR THOIN FABRICE



SAOS SNA SCM

RISQUE CARDIOMÉTABOLIQUE

- 1 / EPIDÉMIOLOGIE ET PUBLICATIONS LE REM
- 2 / UN LIEN PHYSIOPATHOLOGIQUE PRÉCOCE ! LE SNA
- 3 / SAOS AU TRAVERS DE 2 TRAJECTOIRES : FEMME ENCEINTE ET BARIATRIQUE
- 4 / PHENOTYPE LE COMISA
- 5 / PRISE EN CHARGE MULTIMODALE KINE ou RHD TCC PPC / SNA

DR THOIN FABRICE




MORTALITY AND MORBIDITY IN OBSTRUCTIVE SLEEP APNOEA-HYPOPNOEA SYNDROME: RESULTS FROM A 30-YEAR PROSPECTIVE COHORT STUDY

SOPHIE DODDS 2020

OBSERVANCE EN REM

Cohort arm No
CPAP On CPAP
No CPAP, censored
On CPAP, censored

SOPHIE DODDS 2020 ERJ



prospective, cohort study comprised 4502 patients

MYOCARDIAL INFARCTION 29/659 (4.4%) 35/198 (17.7%) <0.001

BAISSE DE 30 À 39 % INCIDENCE DIABETE TYPE II SOUS PPC

27.9% versus 18.7%, p=0.003

Results of imputation analysis of CPAP use and long-term survival in 4502 patients


CPAP use ratio	Relative risk of mortality ratio	Lower 95% CI	Upper 95% CI	p-value
No use/short-term use	3.14	2.69	3.66	<0.001
No use/long-term use	5.63	4.83	6.58	<0.001
Short-term us/ long-term use	1.74	1.49	2.02	<0.001

long-term CPAP users (>5 years) were 5.63 times more likely to be alive at study end than non-CPAP users



IAH EN REM CORRELE A L HG GLYQUEE ET AU RCV

multivariate linear regression model



4 H CPAP USE WOULD LEAVE 60% OF REM SLEEP UNTREATED AND WOULD BE ASSOCIATED WITH A DECREASE IN HBA_{1C} 0.25%.
7 H CPAP USE WOULD COVER MORE THAN 85% OF REM SLEEP AND WOULD BE ASSOCIATED WITH A DECREASE IN HBA_{1C} BY AS 1%.

[Sleep](#). 2021 Feb; 44(2): zsa229.


Published online 2020 Nov 9. doi: [10.1093/sleep/zsa229](https://doi.org/10.1093/sleep/zsa229)

PMCID: PMC7879410

PMID: 33165616

Randomized clinical trials of cardiovascular disease in obstructive sleep apnea: understanding and overcoming bias

Allan I Pack,¹ Ulysses J Magalang,² Bhajan Singh,³ Samuel T Kuna,⁴ Brendan T Keenan,^{1,5} and Greg Maislin^{1,5}



BAISSE DE 1.9 mmhg SBP et 1 mmhg DBP / 1 H PPC

Daniela Grimaldi Diabetes Care 2014

The HIPARCO Randomized Clinical Trial jama 2013

SAOS FDR PRIMAIRE DES MALADIES CV ET MÉTABOLIQUES ? RÔLE DU SOMMEIL PARADOXAL

- Cohorte de la Wisconsin Sleep Cohort Study.
- PSG, 1453 patients, étude du métabolisme glucidique
- $AHI_{NREM} < 8,3/h$

Résistance à
l'insuline associée
à IAH REM





Figure 1. Homeostatic model assessment (HOMA) index by AHI_{REM} category, in participants with $AHI_{NREM} < 8,3$ events/h, n = 1,177. Demographic variables: age, sex, race, study site. AHI = apnea-hypopnea index; BMI = body mass index; sleep time = self-reported usual sleep time; waist = waist circumference.

AHIREM was only associated with HOMA-IR ($\beta = 0.04$; 95% CI, 0.1-0.07; P = 0.01),

Chami. Am J Respir Crit Care 2015

IAH REM $\geq 30/h$
FDR à 9,5 ans
MACES OR 2,41

1. COHORTE DE LA SLEEP HEART HEALTH STUDY.
2. PSG, 3265 PATIENTS AVEC IAH NON-REM $< 5/h$
3. SUIVI MEDIAN DE 9,5 ANS (ÉVÉNEMENTS DÉCÈS CV OU IDM, REVASCULARISATION CORONAIRE, IC, AVC)



Aurora. Am J Respir Crit Care 2018

A Systematic Review and Meta-analysis of Randomized Controlled Trials


Shahrokh Javaheri; Miguel Angel Martinez-Garcia; Francisco Campos-Rodriguez; Alfonso Muriel; Yüksel Peker

improved the **primary composite outcome RR 0.68** [95% CI, 0.50 to 0.92]; P=0.01, and RD -0.05 [95% CI, -0.09 to -0.003], P=0.001

CPAP use also improved cerebrovascular composite outcome RR 0.59

[95% CI, 0.39 to 0.89]; P=0.01, and RD -0.05 [95% CI -0.04 to 0.01], P=0.001; I² :0%; p=0.55),

but not the cardiac composite outcome




Am j resp critc care med 2020


PHYSIOPATHOLOGIE

**INFLUENCE DU SNA
FONCTION ENDOTHELIALE,
SENSIBILITE A L INSULINE ,HVG ,IVG**

SAOS et SNA




OUTILS DE DETECTION ET SNA



Baguet JP et al. Rev Med Interne 2003



POPULATION < 30 ANS SURPOIDS

Sympathetic activation is associated to Sub Clinical Organ Damage



Lambert E Hypertension. 2010

Muscle SNA is influenced by the presence of elevated blood pressure, insulin sensitivity and dyslipidemia



Influence of CPAP on SNS ac





TABLE 2. ENDPOINT OUTCOME MEASURES

Control Group	(n = 21)	CPAP Group (n = 19)	p Value*
LVEF, %			
Baseline	33.6 ± 2.6	37.6 ± 2.5	
3 mo	35.1 ± 3.1	42.6 ± 0.3	
Δ	1.5 ± 1.4	5.0 ± 1.0 [†]	0.04
UNE, nmol/mmol creatinine			
Baseline	21.3 ± 1.9	23.5 ± 4.8	
3 mo	22.9 ± 3.9	13.7 ± 2.5	
Δ	1.6 ± 3.7	-9.9 ± 3.6 [†]	0.036

Mansfield et al, Am J Respir Crit Care Med, 2004




DE LA NECESSITE
D'UNE PRISE EN
CHARGE PRECOCE

IMPACT OSA ENFANT GLYCEMIE HOMA IR HDL

- Fasting plasma insulin (FPI, $14.4 \pm 9.4 \rightarrow 12.6 \pm 9.7 \mu\text{IU/mL}$, $P = .008$),
- homeostasis model assessment-IR ($3.05 \pm 2.13 \rightarrow 2.62 \pm 2.22$, $P = .005$), and
- high-density lipoprotein (HDL) ($51.0 \pm 12.9 \rightarrow 56.5 \pm 14.4 \text{ mg/dL}$, $P = .007$)
improved despite increased BMI z score ($1.43 \pm 0.78 \rightarrow 1.52 \pm 0.62$, $P = .001$)

OSA in < 25% of all children and only 10% of obese children

SENSIBILITE A L INSULINE
corrélée à l IAH résiduel post AA



Metabolic syndrome: a sympathetic disease?


Markus Schlaich, Nora Straznicky, Elisabeth Lambert, Gavin Lambert

Metabolic syndrome is associated with adverse health outcomes and is a growing problem worldwide. Although efforts to harmonise the definition of metabolic syndrome have helped to better understand the prevalence and the adverse outcomes associated with the disorder on a global scale, the mechanisms underpinning the metabolic



Lancet Diabetes Endocrinol 2014

Published Online
April 2, 2014




ORIGINAL ARTICLE

Eight Hours of Nightly Continuous Positive Airway Pressure Treatment of Obstructive Sleep Apnea Improves Glucose Metabolism in Patients with Prediabetes A Randomized Controlled Trial



Sushmita Pamidi¹, Kristen Wroblewski², Magdalena Stepien³, Khalid Sharif-Sidi³, Jennifer Kilkus³, Harry Whitmore³, and Esra Tasali³

¹Respiratory Division, Department of Medicine, McGill University, Montreal, Quebec, Canada; and ²Department of Public Health Sciences and ³Department of Medicine, University of Chicago, Chicago, Illinois

area under the curve for glucose during 2-hour oral glucose tolerance testing



Odi iah rera residuels



2 semaines
8h PPC /nuit pré-diabète



n = 26 or oral placebo n = 13

// noradrenaline

- ❑ The overall glucose response was reduced (-1,276.9[mg/dl]· min [95% CI, -2,392.4 to -161.5]; P =0.03)
- ❑ insulin sensitivity was improved (: 0.77 [mU/L](-1) · min(-1) [95% CI, 0.03-1.52]; P = 0.04)
- ❑ norepinephrine levels and 24-hour blood pressure were reduced


ENDOTHELIAL NITRIC OXIDE SYNTHASE UNCOUPLING: A NOVEL PATHWAY IN OSA INDUCED VASCULAR ENDOTHELIAL DYSFUNCTION

Saradhadevi Varadharaj, Ohio State University, Columbus, OH



FONCTION ENDOTHELIALE ET SAOS CHEZ L'ENFANT SENSIBILITÉ À L'INSULINE

Circulating Plasma Extracellular Microvesicle MicroRNA Cargo and Endothelial Dysfunction in Children with Obstructive Sleep Apnea




ENDOTHELIAL FUNCTION IN CHILDREN WITH OSA
EFFECTS OF ADENOTONSILLECTOMY

- expression of exosomal miRNA-630
 - reduced in children with ED
 - normalized after therapy

Plasma exosomes

- obese children
 - or nonobese children with OSA from endothelial cell
- RECAPITULATED ED**
- in naive human endothelial cells and also
 - *in vivo* when injected into mice



CHILDHOOD OSA IS AN INDEPENDENT DETERMINANT OF BLOOD PRESSURE IN ADULTHOOD
longitudinal follow-up study

TROS A 10 ANS HTA A 20 OR = 2.06

[Kate Ching-Ching Chan](#) THORAX 2020


47 HYPERTENSIVE PATIENTS (66.2%) BECAME NONHYPERTENSIVE AFTER SURGERY.

Characteristic	AT (n = 32)			Non-AT (n = 31)		
	Baseline	Reassessment	P Value ^a	Baseline	Reassessment	P Value ^a
Age, y	9.9 ± 2.6	10.7 ± 2.6	< .001	10.6 ± 3.1	11.3 ± 2.9	< .001
FMD %	7.7 ± 1.5	8.5 ± 1.2	< .001	8.5 ± 1	8.1 ± 0.9	.71

KATE C, CHEST JANUARY 2015

A khalyfa American Journal of Respiratory and Critical Care 2016

cho-hsueh lee Jama 2018




CARDIOVASCULAR DISEASE FROM CRADLE TO GRAVE

younger, more obese, had more severe OSA (higher AHI and TST90) and more cardiovascular risks, in whom regular CPAP was associated with a lower risk of MACEs HR:0.49, 95% CI 0.25 to 0.95)

Pei-Hang Xu, BMJ 2022

EIM (AHI \geq 50) (WMD = 0.073, 95%CI = 0.022 to 0.124, Z = 2.80, p = 0.005)



After a certain amount of training in pediatrics, I concluded that there is no difference between pediatric medicine and adult medicine. Everything starts during childhood, and **what we see in adults is the result of what happened during childhood.**"

C Guillemainault



Li da chen plos one 2017

TRAJECTOIRE AU TRAVERS DE 2 EXEMPLES


CHIRURGIE BARIATRIQUE
FEMME ENCEINTE

COMISA

SOMMEIL ET VISION CARDIO MÉTABOLIQUE DE LA CHIRURGIE BARIATRIQUE



Non-OSA 198 175 135 95 61 64 Numbers
OSA 198 160 115 61 30 at risk



	Non-OSA (n=198)	OSA (n=198)	P-value
2.5%	11.1%	<.001	
2.0%	6.6%	<.001	
0.5%	4.5%	.010	
0.5%	5.1%	.006	
0.5%	2.5%	.177	
3.5%	5.1%	.457	

type 2 diabetes remitted in 66 of 88 patients (75%) at 2 years, in 54 of 87 patients (62%) at 6 years, and in 43 of 84 patients (51%) at 12 years (BYPASS)

OSA HR: 6.92, 95% CI: 3.39–14.13, p < 0.001 remained an independent predictor of CV events after multivariate analysis

830 PATIENTS
LAPARO SLEEVE OU BYP
27 % OSA - 27 KG

sos study Lars Sjöström JAMA 2014

Ted D. Adams N Engl J Med. 2017

Dalmar sleepj 2018


CONGRÈS ANNUEL
DE LA SOCIÉTÉ FRANÇAISE ET FRANCOPHONE
DE CHIRURGIE DE L'OBÉSITÉ
ET DES MALADIES MÉTABOLIQUES



PREGNANCY OFFERS AN OPPORTUNITY TO IDENTIFY WOMEN AT-RISK OF FUTURE CVD


Zaher Armaly 2018 frontier in neurology

“ Les mères présentent une predisposition génétique de pathologie cardiovasculaire en conséquence ,la prééclampsie correspond plus à un stress-test qu'à une pathologie autonome ”



HTA GRAVIDIQUE	OR 1.8
PREECLAMPSIE	2.19
DIABETE GESTATIONNEL	1.60
PRETERME	1.75

VULNERABILITE SNA ET ENDOTHELIALE



Edwards Am J hypert. 2001

Sattar N . BMJ 2002;

- Cluster analysis:
- - To detect patterns of association in symptoms
- - No assumptions or a priori hypotheses


SAOS ET PHENOTYPE

THE DIFFERENT CLINICAL FACES OF OBSTRUCTIVE SLEEP APNOEA: A CLUSTER ANALYSIS

Cluster 1: **DISTURBED SLEEP GROUP (32.7%)**

Cluster 2: **MINIMALLY SYMPTOMATIC GROUP (24.7%)**

Cluster 3: **EXCESSIVELY SLEEPY GROUP (42.6%)**



INSOMNIE ET SAOS LE COMISA

Co-Morbid Insomnia and Sleep Apnea (COMISA): Prevalence, Consequences, Methodological Considerations, and Recent Randomized Controlled Trials

Alexander Sweetman, brain science 2019




Figure 1. History of research in co-morbid insomnia and sleep apnea, including Guilleminault and colleague's 1973 article, and a lack of widespread research attention until two articles by Lichstein and colleagues (1999) and Krakow and colleagues (2001).

SYMPTOMATOLOGIE FRAGMENTATION SNA




COMISA and incident hypertension in our fully adjusted models ([OR], 2.09; 95% [CI], 1.45–3.00) compared with SDB alone (OR, 1.55; 95% CI, 1.14–2.09)

11,623 Hispanic/Latino participants in the Hispanic Community Health Study/Study of Latinos (visit 1, 2008–2011; visit 2, 2014–2017)
IAH 5 WHIIRC 9

SDB was associated with

- 1.54 higher adjusted odds of **INCIDENT HYPERTENSION** (95% [CI], 1.18–2.00)
- 1.33 higher odds of **INCIDENT DIABETES** (95% CI, 1.05–1.67) compared with no SDB.

Insomnia was associated with incident hypertension (odds ratio, 1.37; 95% CI, 1.11–1.69)



ZINCHUK THORAX 2018


Table E3. Effect estimates from survey logistic regression models for the association between comorbid SDB and insomnia and 6-year incident hypertension (N=6965) / diabetes (N=8023), HCHS/SOL (2008–2017)

	Model 1		Model 2		Model 3	
	OR	[95% CI]	OR	[95% CI]	OR	[95% CI]
Hypertension						
Comorbid SDB and insomnia						
Neither SDB nor insomnia (ref)						
SDB	3.37	[2.62, *** 4.34]	1.94	[1.46, ** 2.57]	1.55	[1.14, ** 2.09]
Insomnia	1.82	[1.43, *** 2.31]	1.43	[1.09, ** 1.88]	1.37 *	[1.04, 1.81]
SDB & insomnia	5.23	[3.87, *** 7.07]	2.73	[1.94, *** 3.85]	2.09	[1.45, *** 3.00]
Diabetes						
Comorbid SDB and insomnia						
Neither SDB nor insomnia (ref)						
SDB	3.35	[2.64, *** 4.26]	2.30	[1.76, *** 2.99]	1.46	[1.10, ** 1.93]
Insomnia	1.58	[1.19, ** 2.12]	1.36 *	[1.00, 1.86]	1.25	[0.91, 1.72]
SDB & insomnia	3.83	[2.81, *** 5.21]	2.36	[1.71, *** 3.26]	1.41 *	[1.00, 1.99]


Li Am J Respir Crit Care Med 2021

COMISA RISQUE MAJEUR

5236 2221 (42%) had OSA-alone, and 137 (3%) had COMISA



- COMISA was associated with a **47% (HR, 95% CI; 1.47 (1.06, 2.07)) increased risk of mortality**
- Insomnia-alone and OSA-alone were associated with higher risk of hypertension but not cardiovascular disease



INTERET DU TTT MULTIMODAL et PERSONNALISE




ORL
PNEUMOLOGUE
CARDIOLOGUE
GENERALISTE
ENDOCRINOLOGUE
KINE OROLINGUALE
ORTHODONTISTE
PSYCHIATRE
OSTEOPATHE
COACH SPORTIF
THERAPIE COMPORTEMENTALE
CHIR MAXILOFACIALE
CHIRURGIEN BARIATRIQUE
DENTISTE

1 ENREGISTREMENT PRECOCE

2 KINE OROLINGUAL ORTHOPHONIE





3  SOH pneumo , KINE, ORL stimulation XII, orthodontiste, TCC

4 SPORT RHD



CPAP, WEIGHT LOSS, OR BOTH FOR OBSTRUCTIVE SLEEP APNEA

SYNERGIE HTA HOMA POIDS CRP



■ CPAP alone ■ Weight loss+CPAP ■ Weight loss alone

Chirinos JA



N Engl J Med 2014;370:2265-75

PPC

1 ACTEUR DE SA PRISE EN CHARGE / TRAJECTOIRE

2 ACCEPTABILITE ET OBSERVANCE REM (annonce ,TCC , sport ..)

3 PRESSION ADAPTEE / SNA (EFFORT RESP)



"Our study suggests that there is, in fact, a subgroup of non-sleepy patients with OSA for whom CPAP could provide a reduction in risk—those with a higher pulse rate response to their respiratory events," said Azarbarzin

Somers nejm 1993

Mini Symposium Cardiovascular Benefit of CPAP Is Modified by the Sleep Apnea Related Pulse Rate Response in Coronary Artery Disease Patients with Nonsleepy OSA: Findings from the RICCADSA Randomized Controlled Trial

A. Azarbarzin 1, A. Zinchuk 2, D. Wellman 1, L. Taranto Montemurro 1, D. Vena 1, L. Gell 1, L. Messineo 1, D. White 1, D. J. Gottlieb 1, S. S. Redline 1, Y. Peker 3

- **ΔHR WERE AT INCREASED RISK OF NONFATAL OR FATAL CVD AND ALL-CAUSE MORTALITY** (nonfatal adjusted hazard ratio [95% confidence interval (CI)], 1.60 [1.28-2.00]; fatal adjusted hazard ratio [95% CI], 1.68 [1.22-2.30]; all-cause adjusted hazard ratio [95% CI], 1.29 [1.07-1.55]).
- The risk associated with a high ΔHR was particularly high in those with a substantial hypoxic burden (nonfatal, 1.93 [1.36-2.73]; **fatal, 3.50** [2.15-5.71]; all-cause, 1.84 [1.40-2.40]) and was exclusively observed in **nonsleepy individuals azarbazin mesa sleep heart study**



at elevated ΔHR (10.8 BPM, +1SD) **treatment HR was 0.39** [0.15-0.98]




in contrast to no significant effect at normal ΔHR (7.1 BPM)



NORMALIZED ΔHR MEASURES WERE STRONGER DETERMINANTS OF TREATMENT-RELATED RISK REDUCTION, arousal intensity, and event duration. “Treatment benefit is associated with greater normalized ΔHR (responsiveness) rather than just event severity





MERCI

